6-Piperazin-1-ylpyridin-3-amine;hydrochloride | 82205-56-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 6-Piperazin-1-ylpyridin-3-amine;hydrochloride
• CAS: 82205-56-9
• 化学式: C9H15ClN4
• 分子量: 214.69
• InChiKey: DCTSRXPYHJQJPJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  54.2
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Diacylglycerol Acyltransferase Inhibitors
  申请人：Bolin David Robert

  公开号：US20090093497A1

  公开（公告）日：2009-04-09

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

  本文提供的是公式(I)的化合物，以及其药物可接受的盐，其中取代基如规范中所述。这些化合物和含有它们的药物组合物对于治疗疾病，例如肥胖症、2型糖尿病和代谢综合征是有用的。
• DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS
  申请人：Via Pharmaceuticals, Inc.

  公开号：EP2155687A1

  公开（公告）日：2010-02-24
• KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
  申请人：Courtney Stephen Martin

  公开号：US20140329795A1

  公开（公告）日：2014-11-06

  Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
• US9428464B2
  申请人：——

  公开号：US9428464B2

  公开（公告）日：2016-08-30
• [EN] DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS<br/>[FR] INHIBITEURS DE DIACYLGLYCÉROL ACYLTRANSFÉRASE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2008141976A1

  公开（公告）日：2008-11-27

  [EN] Provided herein are compounds of the formula (I) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.
  [FR] L'invention concerne des composés de la formule (I) ainsi que des sels pharmaceutiquement acceptables de ceux-ci, les substituants étant ceux décrits dans l'invention. Ces composés, et les compositions pharmaceutiques les contenant, sont utiles pour le traitement de maladies telles que, par exemple, l'obésité, le diabète sucré de type II et le syndrome métabolique.